Boehringer Ingelheim's Inhalers for COPD and Asthma Now $35/Month for Eligible Patients

Boehringer Ingelheim has introduced a groundbreaking program aimed at making its inhalers for COPD and asthma more affordable for eligible patients. The initiative, which caps out-of-pocket expenses at $35 monthly, is now accessible, providing financial relief for various patients, including uninsured and those facing high co-pays.

Jean-Michel Boers, President and CEO of Boehringer Ingelheim USA Corporation, emphasized the company's dedication to ensuring that essential medications are within reach for all. "Access to life-saving medicines is a responsibility we take seriously," Boers stated. The $35 cap applies across Boehringer's entire range of inhalers, significantly benefitting vulnerable populations.

From June 1, 2024, patients with commercial insurance will experience the automatic cost reduction at over 90% of participating retail pharmacies nationwide. This seamless application of the discount requires no additional steps from the patients. For those whose pharmacies do not participate or are uninsured, a savings card can be obtained to benefit from the same cost cap.

The program covers a variety of Boehringer Ingelheim inhalers, including:
- Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol
- Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray
- Spiriva® HandiHaler® (tiotropium bromide inhalation powder)
- Spiriva® Respimat® 1.25 mcg (tiotropium bromide) Inhalation Spray
- Spiriva® Respimat® 2.5 mcg (tiotropium bromide) Inhalation Spray
- Stiolto® Respimat® (tiotropium bromide and olodaterol) Inhalation Spray
- Striverdi® Respimat® (olodaterol) Inhalation Spray

Boehringer Ingelheim has long supported patients through various initiatives, including offering savings cards for most of its products to ease the burden of co-payments. Additionally, the Boehringer Cares Foundation provides free medicines to eligible patients, further showcasing the company’s dedication to patient care.

Boehringer Ingelheim is a leading biopharmaceutical company in human and animal health. Founded in 1885, the company remains independent and focuses heavily on research and development. With over 53,500 employees across more than 130 markets, Boehringer Ingelheim is committed to creating a healthier, sustainable, and equitable future.

This new program not only reflects Boehringer Ingelheim’s ongoing efforts to simplify the healthcare system but also aims to set a precedent for predictable and affordable medication costs. This initiative is a significant step towards balancing the healthcare playing field and ensuring that financial constraints do not hinder access to essential treatments.